CRISPR Therapeutics AG (NASDAQ:CRSP) Jefferies London Healthcare Conference November 20, 2024 11:00 AM ET
Company Participants
Samarth Kulkarni – Chief Executive Officer and Chairman
Conference Call Participants
Maury Raycroft – Jefferies
Maury Raycroft
Hi, everyone. My name is Maury Raycroft, I’m one of the biotech analysts at Jeffreys. I’d like to welcome Sam Kulkarni, the CEO of CRISPR Therapeutics. Sam, thanks so much for joining us today.
Samarth Kulkarni
Thank you for having me.
Maury Raycroft
And we’re going to do fireside chat format. So, for maybe for those who are new to the story, if you want to give a one minute intro to CRISPR.
Samarth Kulkarni
Yes, happy to do that. And thanks for having us. We’re now in the 10th year of CRISPR as a company, and it’s been a remarkable journey. We were originally founded based on the Nobel Prize winning discovery, an elucidation of CRISPR/Cas9 as a tool to edit genome. And we’ve applied that tool, powerful tool, to develop transformative medicines, the first of which was directed towards beta thalassemia and sickle cell disease, and we now have an improved drug called Casgevy that’s being launched by our partner Vertex around the world. I’ll talk more about that. But beyond that really we’ve taken the platform and parlayed that into a number of other areas, both rare diseases and common diseases. So we have a platform with CAR-T cells that are best-in-class for oncology as well as autoimmune diseases. We have in vivo gene editing now where we’re in the clinic with programs directed towards cardiovascular risk factors like LPA and ANGPTL3 validated risk factors.
And beyond that, we have our platform in diabetes. We’re going out for solid tumors. We’ve now shown preclinical data for glaucoma in the eye. So I think it’s a pretty broad expansion
Read the full article here
